Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexone

Elisabeth Cw Neefjes, Maurice Jdl van der Vorst, Manon Sa Boddaert, Wouter Wa Zuurmond, Hans J van der Vliet, Aart Beeker, Hendrik P van den Berg, Cornelis J van Groeningen, Suzan Vrijaldenhoven, Henk Mw Verheul, Elisabeth Cw Neefjes, Maurice Jdl van der Vorst, Manon Sa Boddaert, Wouter Wa Zuurmond, Hans J van der Vliet, Aart Beeker, Hendrik P van den Berg, Cornelis J van Groeningen, Suzan Vrijaldenhoven, Henk Mw Verheul

Abstract

Background: Opioid-induced constipation (OIC) is one of the major symptoms in palliative care with a prevalence of 30-50%. Methylnaltrexone for the treatment of OIC is significantly more effective than placebo, but only in about fifty percent of the patients regardless of dose increase. Dose increases cause increased toxicity without additional efficacy, and are therefore not recommended. While methylnaltrexone is a μ-receptor antagonist, only a few opioids are solely μ-receptor agonists. Therefore, the response to methylnaltrexone may be determined by the receptor-profile of a specific opioid. In addition, methylnaltrexone may also affect the immune system and angiogenesis as was found in pre-clinical studies. Primary aim of this study is to determine differences in the efficacy of methylnaltrexone prescribed to resolve opioid induced constipation between three commonly used opioid subtypes: morphine sulphate, oxycodone and fentanyl. Secondary aim is to explore potential immunomodulatory and antiangiogenic effects of methylnaltrexone.

Methods: In this multi-center, prospective, parallel group trial we will evaluate the efficacy of methylnaltrexone in resolving OIC occurring as a side effect of the most common opioid subtypes: morphine, oxycodone and fentanyl. In total 195 patients with OIC despite prophylactic laxatives will receive methylnaltrexone every other day up to fourteen days. Patients will report its effect in a laxation diary. Group allocation is based on the opioid type the patient is using. At the start and end of the study period patients complete the Bowel Function Index questionnaire. A subgroup of the patients will donate blood for analysis of immunomodulatory- and anti-angiogenic effects of methylnaltrexone.

Discussion: In this study we aim to determine the efficacy of methylnaltrexone per opioid subtype to reduce constipation. We expect that the outcome of this study will improve the clinical use of methylnaltraxone.

Trial registration: This trial is registered at clinicaltrials.gov: NCT01955213 and in the Dutch trial register: NTR4272.

Keywords: Angiogenesis; Constipation; Immunomodulation; Methylnaltrexone; Opioids; Palliative care.

Figures

Figure 1
Figure 1
Study flow chart.

References

    1. de Groot JW, Peters FT, Reyners AK. Treatment of constipation in the palliative care phase. Ned Tijdschr Geneeskd. 2010;154A:A2224.
    1. Walsh D, Donnely S, Rybicki L. The symptoms of advanced cancer: relationship to age, gender and performance status in 1,000 patients. Supp Care Cancer. 2000;8:175–179.
    1. van den Beuken-van Everdingen MHJ, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Quality of life and non-pain symptoms in patients with cancer. J Pain Symptom Manage. 2009;38:216–233.
    1. Panchal SJ, Müller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract. 2007;61:1181–1187.
    1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480–1491.
    1. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surgery. 2001;182(Suppl):11S–18S.
    1. Klepstad P, Borchgrevink PC, Kaasa S. Effects on cancer patients’ health-related quality of life after the start of morphine therapy. J Pain Symptom Manage. 2000;20:19–26.
    1. Reid CM, Martin RM, Sterne JA, Davies AN, Hanks GW. Oxycodone for cancer-related pain. Arch Intern Med. 2006;166:837–843.
    1. Thomas J, Karver S, Cooney GA, Chamberlain BH, Watt CK, Slatkin NE, Stambler N, Kremer AB, Israel RJ. Methylnaltrexone for opioid-induced constipation in advanced illness. N Eng J Med. 2008;358:2332–2343.
    1. de Graeff A, Verhagen EH, Besse TC, Crul BJP, Krol RJA. Oncoline – cancer clinical practice guidelines – pain. 2009. .
    1. Swarm R, Abernethy AP, Anghelescu DL, Benedetti C, Blinderman CD, Boston B, Cleeland C, Coyle N, Deleon-Casasola OA, Eilers JG, Ferrell B, Janjan NA, Karver SB, Levy MH, Lynch M, Moryl N, Murphy BA, Nesbit SA, Oakes L, Obbens EA, Paice JA, Rabow MW, Syrjala KL, Urba S, Weinstein SM. Adult cancer pain. J Natl Compr Canc Netw. 2010;8:1046–1086.
    1. Wirz S, Nadstawek J, Elsen C, Junker U, Wartenberg HC. Laxative management in ambulatory cancer patients on opioid therapy: a prospective, open-label investigation of polyethylene glycol, sodium picosulphate and lactulose. Eur J Cancer Care. 2012;21:131–140.
    1. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician. 2008;11(Suppl):S133–S153.
    1. De Luca A, Coupar IM. Insights into opioid action in the intestinal tract. Pharmacol Ther. 1996;69:103–115.
    1. Manara L, Bianchetti A. The central and peripheral influences of opioids on gastrointestinal propulsion. Ann Rev Pharmacol Toxicol. 1985;25:249–273.
    1. Manara L, Bianchi G, Ferretti P, Tavani A. Inhibition of gastrointestinal transit by morphine in rats results primarily from direct drug action on gut opioid sites. J Pharmacol Exp Ther. 1986;237:945–949.
    1. EMA product information annex I. .
    1. Portenoy RK, Thomas J, Moehl Boatwright ML, Tran D, Galasso FL, Stambler N, Von Gunten CF, Israel RJ. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage. 2008;35:458–468.
    1. Mori T, Shibasaki Y, Matsumoto K, Shibasaki M, Hasegawa M, Wang E, Masukawa D, Yoshizawa K, Horie S, Suzuki T. Mechanisms that underlie μ-opioid receptor agonist-induced constipation: differential involvement of μ-opioid receptor sites and responsible regions. J Pharmacol Exp Ther. 2013;347:91–99.
    1. Wybran J, Appelboom T, Fameay JP, Govaerts A. Suggestive evidence for receptors for morphine and methionine-enkephalin on normal human blood T lymphocytes. J of Immunology. 1979;123:1068–1070.
    1. Singleton PA, Lingen MW, Fekete MJ, Garcia JG, Moss J. Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation. Microvasc Res. 2006;72:3–11.
    1. Gupta K, Kshirsagar S, Chang L, Schwartz R, Law PY, Yee D, Hebbel RP. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res. 2002;62:4491–4498.
    1. Roy S, Barke RA, Loh HH. Mu-opioid receptor-knockout mice: role of mu-opioid receptor in morphine mediated immune functions. Brain Res Mol Brain Res. 1998;61:190–194.
    1. Finn OJ. Cancer immunology. N Engl J Med. 2008;358:2704–2715.
    1. Makarenkova VP, Esche C, Kost NV, Shuring GV, Rabin BS, Zozulya AA, Shurin MR. Identification of delta- and mu-type opioid receptors on human and murine dendritic cells. J Neuroimmunol. 2001;117:68–77.
    1. Chuang TK, Killam KF, Chuang LF, Kung HF, Sheng WS, Chao CC, Yu L, Chuang RJ. Mu opioid receptor gene expression in immune cells. Biochem Biophys Res Commun. 1995;216:923–930.
    1. Vallejo R, de Leon-Casasola O, Benyamin R. Opioid therapy and immunosuppression. A review. Am J Ther. 2004;11:354–365.
    1. Yossuck P, Nightengale BJ, Fortney JE, Gibson LF. Effect of morphine sulfate on neonatal neutrophil chemotaxis. Clin J Pain. 2008;24:76–82.
    1. Tseng RJ, Padgett DA, Dhabhar FS, Engler H, Sheridan JF. Stress-induced modulation of NK activity during influenza viral infection: role of glucocorticoids and opioids. Brain Behav Immun. 2005;19:153–164.
    1. Singleton PA, Garcia JGN, Moss J. Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis. Mol Cancer Ther. 2008;7:1669–1679.
    1. Cadet P, Mantione KJ, Bilfinger TV, Stefano GB. Differential expression of the human mu opiate receptor from different primary vascular endothelial cells. Med Sci Monit. 2004;10:BR351–BR355.
    1. Rentz AM, Yu R, Müller-Lissner S, Leyendecker P. Validation of the bowel function index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ. 2009;12:371–383.
    1. Mackey AC, Green L, Greene P, Avigan M. Methylnaltrexone and gastrointestinal perforation. J Pain Symptom Manege. 2010;40:e1–e3.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren